abstract |
The present disclosure relates to methods of treating a cancer (or a tumor) with an IL-7 protein in combination with an immune checkpoint inhibitor, such as a PD-1 antagonist (e.g., anti-PD-1 antibody) or a CTLA-4 antagonist (e.g., anti-CTLA-4 antibody). |